scopolamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2424 | 51-34-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.90 | mg | O |
| 0.90 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 666.67 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 27 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 3.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.50 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 31, 1979 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mydriasis | 102.67 | 15.16 | 43 | 7967 | 11913 | 63469099 |
| Anticholinergic syndrome | 90.31 | 15.16 | 26 | 7984 | 2356 | 63478656 |
| Akathisia | 72.23 | 15.16 | 31 | 7979 | 9115 | 63471897 |
| Vomiting | 37.94 | 15.16 | 155 | 7855 | 559462 | 62921550 |
| Product adhesion issue | 37.27 | 15.16 | 16 | 7994 | 4703 | 63476309 |
| High density lipoprotein decreased | 33.65 | 15.16 | 12 | 7998 | 2158 | 63478854 |
| Neutrophil count increased | 29.61 | 15.16 | 21 | 7989 | 16506 | 63464506 |
| Infectious mononucleosis | 27.36 | 15.16 | 10 | 8000 | 1929 | 63479083 |
| Application site rash | 24.89 | 15.16 | 10 | 8000 | 2488 | 63478524 |
| Progressive multiple sclerosis | 24.04 | 15.16 | 8 | 8002 | 1170 | 63479842 |
| Vision blurred | 23.70 | 15.16 | 42 | 7968 | 91882 | 63389130 |
| Nausea | 23.09 | 15.16 | 185 | 7825 | 854286 | 62626726 |
| Differential white blood cell count abnormal | 22.90 | 15.16 | 7 | 8003 | 779 | 63480233 |
| Red cell distribution width increased | 22.71 | 15.16 | 15 | 7995 | 10509 | 63470503 |
| Hallucination | 22.46 | 15.16 | 31 | 7979 | 54786 | 63426226 |
| Tachyarrhythmia | 22.30 | 15.16 | 11 | 7999 | 4439 | 63476573 |
| Suicidal ideation | 20.78 | 15.16 | 32 | 7978 | 62389 | 63418623 |
| Blood lactic acid increased | 20.07 | 15.16 | 12 | 7998 | 7074 | 63473938 |
| Arthropathy | 19.80 | 15.16 | 3 | 8007 | 234789 | 63246223 |
| Tachycardia | 19.68 | 15.16 | 45 | 7965 | 118111 | 63362901 |
| Cytarabine syndrome | 19.52 | 15.16 | 4 | 8006 | 85 | 63480927 |
| Salivary hypersecretion | 19.19 | 15.16 | 12 | 7998 | 7654 | 63473358 |
| Drug ineffective | 19.06 | 15.16 | 68 | 7942 | 1044697 | 62436315 |
| Application site reaction | 19.00 | 15.16 | 6 | 8004 | 744 | 63480268 |
| Long QT syndrome congenital | 18.86 | 15.16 | 4 | 8006 | 101 | 63480911 |
| Joint swelling | 18.68 | 15.16 | 9 | 8001 | 327657 | 63153355 |
| Application site erythema | 18.58 | 15.16 | 10 | 8000 | 4825 | 63476187 |
| Alopecia | 18.16 | 15.16 | 10 | 8000 | 337526 | 63143486 |
| Colitis | 17.75 | 15.16 | 26 | 7984 | 48502 | 63432510 |
| Hyperkinesia | 17.60 | 15.16 | 7 | 8003 | 1697 | 63479315 |
| Cardiac output decreased | 17.47 | 15.16 | 6 | 8004 | 966 | 63480046 |
| Small intestinal obstruction | 17.27 | 15.16 | 16 | 7994 | 18321 | 63462691 |
| Intra-abdominal haematoma | 17.21 | 15.16 | 7 | 8003 | 1798 | 63479214 |
| Disorientation | 17.20 | 15.16 | 23 | 7987 | 39429 | 63441583 |
| Blood alkaline phosphatase increased | 17.15 | 15.16 | 24 | 7986 | 42943 | 63438069 |
| Antipsychotic drug level above therapeutic | 17.05 | 15.16 | 6 | 8004 | 1037 | 63479975 |
| Systemic lupus erythematosus | 16.87 | 15.16 | 3 | 8007 | 208915 | 63272097 |
| Abdominal pain | 16.51 | 15.16 | 77 | 7933 | 293379 | 63187633 |
| Porphyria acute | 16.34 | 15.16 | 6 | 8004 | 1171 | 63479841 |
| Drug monitoring procedure incorrectly performed | 16.13 | 15.16 | 4 | 8006 | 204 | 63480808 |
| Dehydration | 15.84 | 15.16 | 53 | 7957 | 173301 | 63307711 |
| Delirium | 15.56 | 15.16 | 25 | 7985 | 50516 | 63430496 |
| Infusion related reaction | 15.17 | 15.16 | 6 | 8004 | 245515 | 63235497 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutrophil count increased | 79.89 | 17.83 | 45 | 6088 | 17101 | 34933697 |
| Prescription drug used without a prescription | 76.05 | 17.83 | 24 | 6109 | 2130 | 34948668 |
| Failure to suspend medication | 64.21 | 17.83 | 15 | 6118 | 423 | 34950375 |
| Neuroleptic malignant syndrome | 54.98 | 17.83 | 36 | 6097 | 17898 | 34932900 |
| Antipsychotic drug level increased | 51.81 | 17.83 | 21 | 6112 | 3844 | 34946954 |
| White blood cell count increased | 50.29 | 17.83 | 48 | 6085 | 41103 | 34909695 |
| Wrong patient received product | 41.08 | 17.83 | 16 | 6117 | 2638 | 34948160 |
| Toxicity to various agents | 40.05 | 17.83 | 100 | 6033 | 200262 | 34750536 |
| Accidental death | 38.70 | 17.83 | 15 | 6118 | 2441 | 34948357 |
| Antipsychotic drug level decreased | 34.52 | 17.83 | 11 | 6122 | 1006 | 34949792 |
| Platelet count decreased | 34.26 | 17.83 | 69 | 6064 | 119648 | 34831150 |
| Salivary hypersecretion | 33.13 | 17.83 | 20 | 6113 | 8624 | 34942174 |
| Ideas of reference | 32.61 | 17.83 | 6 | 6127 | 49 | 34950749 |
| White blood cell count decreased | 32.20 | 17.83 | 59 | 6074 | 95386 | 34855412 |
| Platelet count increased | 31.34 | 17.83 | 20 | 6113 | 9506 | 34941292 |
| Confusional state | 30.93 | 17.83 | 74 | 6059 | 144086 | 34806712 |
| Lymphocyte count decreased | 30.72 | 17.83 | 28 | 6105 | 22594 | 34928204 |
| Differential white blood cell count abnormal | 30.63 | 17.83 | 11 | 6122 | 1448 | 34949350 |
| Vomiting | 30.53 | 17.83 | 104 | 6029 | 247517 | 34703281 |
| Pneumonia aspiration | 28.61 | 17.83 | 36 | 6097 | 41867 | 34908931 |
| Neutrophil count decreased | 27.38 | 17.83 | 39 | 6094 | 51065 | 34899733 |
| Hallucination | 27.14 | 17.83 | 39 | 6094 | 51459 | 34899339 |
| Red blood cell elliptocytes present | 26.65 | 17.83 | 6 | 6127 | 143 | 34950655 |
| Seizure | 24.85 | 17.83 | 56 | 6077 | 104801 | 34845997 |
| Incision site pain | 24.67 | 17.83 | 10 | 6123 | 1828 | 34948970 |
| Portal tract inflammation | 24.33 | 17.83 | 5 | 6128 | 76 | 34950722 |
| Incorrect product dosage form administered | 24.32 | 17.83 | 6 | 6127 | 214 | 34950584 |
| Pneumoconiosis | 23.98 | 17.83 | 6 | 6127 | 227 | 34950571 |
| Serotonin syndrome | 23.85 | 17.83 | 23 | 6110 | 19910 | 34930888 |
| Mydriasis | 23.32 | 17.83 | 15 | 6118 | 7222 | 34943576 |
| Schizophrenia | 23.20 | 17.83 | 16 | 6117 | 8650 | 34942148 |
| Agitation | 22.60 | 17.83 | 38 | 6095 | 57361 | 34893437 |
| Product adhesion issue | 22.50 | 17.83 | 9 | 6124 | 1591 | 34949207 |
| Volvulus | 22.32 | 17.83 | 9 | 6124 | 1623 | 34949175 |
| Drug ineffective | 21.87 | 17.83 | 29 | 6104 | 456722 | 34494076 |
| Body temperature increased | 20.70 | 17.83 | 20 | 6113 | 17348 | 34933450 |
| Mental impairment | 20.69 | 17.83 | 16 | 6117 | 10306 | 34940492 |
| Mean cell volume decreased | 20.19 | 17.83 | 8 | 6125 | 1380 | 34949418 |
| Convulsive threshold lowered | 19.01 | 17.83 | 6 | 6127 | 532 | 34950266 |
| Hepatic steatosis | 17.96 | 17.83 | 19 | 6114 | 18343 | 34932455 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutrophil count increased | 113.79 | 14.64 | 65 | 12029 | 29331 | 79702963 |
| Mydriasis | 84.76 | 14.64 | 45 | 12049 | 17598 | 79714696 |
| Anticholinergic syndrome | 78.82 | 14.64 | 27 | 12067 | 3584 | 79728710 |
| Neuroleptic malignant syndrome | 68.58 | 14.64 | 46 | 12048 | 27513 | 79704781 |
| Akathisia | 67.04 | 14.64 | 35 | 12059 | 13224 | 79719070 |
| Vomiting | 62.68 | 14.64 | 232 | 11862 | 665596 | 79066698 |
| Failure to suspend medication | 59.88 | 14.64 | 14 | 12080 | 460 | 79731834 |
| White blood cell count increased | 56.58 | 14.64 | 63 | 12031 | 74570 | 79657724 |
| Differential white blood cell count abnormal | 55.15 | 14.64 | 18 | 12076 | 2059 | 79730235 |
| Antipsychotic drug level increased | 52.38 | 14.64 | 23 | 12071 | 5934 | 79726360 |
| Wrong patient received product | 44.43 | 14.64 | 19 | 12075 | 4599 | 79727695 |
| Hallucination | 41.81 | 14.64 | 58 | 12036 | 85687 | 79646607 |
| Lymphocyte count decreased | 41.24 | 14.64 | 43 | 12051 | 47246 | 79685048 |
| Salivary hypersecretion | 38.43 | 14.64 | 25 | 12069 | 14199 | 79718095 |
| Accidental death | 35.90 | 14.64 | 16 | 12078 | 4275 | 79728019 |
| Antipsychotic drug level above therapeutic | 35.67 | 14.64 | 13 | 12081 | 2067 | 79730227 |
| Seizure | 35.16 | 14.64 | 84 | 12010 | 188750 | 79543544 |
| Drug ineffective | 34.73 | 14.64 | 70 | 12024 | 1080843 | 78651451 |
| Platelet count decreased | 34.54 | 14.64 | 85 | 12009 | 194579 | 79537715 |
| White blood cell count decreased | 34.24 | 14.64 | 83 | 12011 | 188205 | 79544089 |
| Neutrophil count decreased | 33.60 | 14.64 | 55 | 12039 | 93904 | 79638390 |
| Incision site pain | 31.78 | 14.64 | 13 | 12081 | 2817 | 79729477 |
| Antipsychotic drug level decreased | 30.06 | 14.64 | 10 | 12084 | 1214 | 79731080 |
| Confusional state | 29.92 | 14.64 | 111 | 11983 | 317886 | 79414408 |
| High density lipoprotein decreased | 28.54 | 14.64 | 14 | 12080 | 4641 | 79727653 |
| Arthralgia | 28.36 | 14.64 | 27 | 12067 | 571776 | 79160518 |
| Constipation | 27.63 | 14.64 | 100 | 11994 | 282950 | 79449344 |
| Agitation | 27.40 | 14.64 | 52 | 12042 | 99663 | 79632631 |
| Ideas of reference | 26.73 | 14.64 | 6 | 12088 | 164 | 79732130 |
| Pneumonia aspiration | 26.41 | 14.64 | 41 | 12053 | 66926 | 79665368 |
| Platelet count increased | 26.33 | 14.64 | 24 | 12070 | 22382 | 79709912 |
| Red blood cell elliptocytes present | 25.41 | 14.64 | 6 | 12088 | 206 | 79732088 |
| Volvulus | 25.24 | 14.64 | 11 | 12083 | 2785 | 79729509 |
| Tachycardia | 24.79 | 14.64 | 71 | 12023 | 177697 | 79554597 |
| Pneumoconiosis | 24.47 | 14.64 | 6 | 12088 | 242 | 79732052 |
| Serotonin syndrome | 24.28 | 14.64 | 32 | 12062 | 44995 | 79687299 |
| Incorrect product dosage form administered | 23.20 | 14.64 | 6 | 12088 | 301 | 79731993 |
| Portal tract inflammation | 22.66 | 14.64 | 5 | 12089 | 126 | 79732168 |
| Blood alkaline phosphatase increased | 22.39 | 14.64 | 37 | 12057 | 63627 | 79668667 |
| Progressive multiple sclerosis | 22.34 | 14.64 | 8 | 12086 | 1209 | 79731085 |
| Joint swelling | 22.23 | 14.64 | 8 | 12086 | 288638 | 79443656 |
| Mental impairment | 21.61 | 14.64 | 20 | 12074 | 19016 | 79713278 |
| Dyskinesia | 21.38 | 14.64 | 30 | 12064 | 44743 | 79687551 |
| Convulsive threshold lowered | 20.35 | 14.64 | 7 | 12087 | 940 | 79731354 |
| Rheumatoid arthritis | 19.38 | 14.64 | 4 | 12090 | 208466 | 79523828 |
| Red cell distribution width increased | 19.24 | 14.64 | 17 | 12077 | 15225 | 79717069 |
| Application site erythema | 18.96 | 14.64 | 11 | 12083 | 5099 | 79727195 |
| Antipsychotic drug level below therapeutic | 18.52 | 14.64 | 7 | 12087 | 1231 | 79731063 |
| Product administered to patient of inappropriate age | 18.11 | 14.64 | 11 | 12083 | 5542 | 79726752 |
| Cytarabine syndrome | 18.08 | 14.64 | 4 | 12090 | 102 | 79732192 |
| Haemoglobin decreased | 17.99 | 14.64 | 74 | 12020 | 222045 | 79510249 |
| Hepatic steatosis | 17.60 | 14.64 | 25 | 12069 | 37713 | 79694581 |
| Arthropathy | 17.31 | 14.64 | 3 | 12091 | 177108 | 79555186 |
| Muscle rigidity | 17.19 | 14.64 | 18 | 12076 | 19864 | 79712430 |
| Musculoskeletal stiffness | 17.02 | 14.64 | 3 | 12091 | 175005 | 79557289 |
| Infusion related reaction | 16.70 | 14.64 | 7 | 12087 | 230230 | 79502064 |
| Mean cell volume decreased | 16.65 | 14.64 | 10 | 12084 | 4937 | 79727357 |
| Somnolence | 16.59 | 14.64 | 76 | 12018 | 238905 | 79493389 |
| Dehydration | 16.54 | 14.64 | 78 | 12016 | 248109 | 79484185 |
| Long QT syndrome congenital | 16.52 | 14.64 | 4 | 12090 | 153 | 79732141 |
| Drug intolerance | 16.22 | 14.64 | 10 | 12084 | 264109 | 79468185 |
| Delirium | 16.11 | 14.64 | 38 | 12056 | 84589 | 79647705 |
| Body temperature increased | 15.87 | 14.64 | 26 | 12068 | 44394 | 79687900 |
| Electrocardiogram QT prolonged | 15.51 | 14.64 | 39 | 12055 | 90347 | 79641947 |
| Alopecia | 15.29 | 14.64 | 8 | 12086 | 231347 | 79500947 |
| Swelling | 15.07 | 14.64 | 7 | 12087 | 216704 | 79515590 |
| Hallucination, auditory | 14.87 | 14.64 | 17 | 12077 | 20676 | 79711618 |
| Abdominal discomfort | 14.70 | 14.64 | 10 | 12084 | 250717 | 79481577 |
| Apnoea | 14.67 | 14.64 | 13 | 12081 | 11691 | 79720603 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A04AD01 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics |
| ATC | A04AD51 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics |
| ATC | N05CM05 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives |
| ATC | S01FA02 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics |
| FDA MoA | N0000175370 | Cholinergic Antagonists |
| FDA EPC | N0000175574 | Anticholinergic |
| MeSH PA | D000759 | Adjuvants, Anesthesia |
| MeSH PA | D000932 | Antiemetics |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D009184 | Mydriatics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| CHEBI has role | CHEBI:25212 | metabolites |
| CHEBI has role | CHEBI:35469 | antidepressants |
| CHEBI has role | CHEBI:48876 | muscarinic antagonists |
| CHEBI has role | CHEBI:50513 | mydriatics |
| CHEBI has role | CHEBI:50919 | antiemetico |
| CHEBI has role | CHEBI:53784 | antispasmodics |
| CHEBI has role | CHEBI:60807 | anaesthestic adjuvant |
| CHEBI has role | CHEBI:60809 | adjuvants |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Irritable bowel syndrome | indication | 10743008 | DOID:9778 |
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Motion sickness | indication | 37031009 | DOID:2951 |
| Dilated pupil | indication | 37125009 | |
| Cough | indication | 49727002 | |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Cycloplegia | indication | 68158006 | DOID:10033 |
| Nasal congestion | indication | 68235000 | |
| Iridocyclitis | indication | 77971008 | |
| Common cold | indication | 82272006 | DOID:10459 |
| Posterior synechiae | indication | 111512005 | |
| Uveitis | indication | 128473001 | DOID:13141 |
| Prevention of Posterior Synechiae | indication | ||
| Perioperative Mydriasis | indication | ||
| Prevention of Motion Sickness | indication | ||
| Prevention of Post-Operative Nausea and Vomiting | indication | ||
| General anesthesia | off-label use | 50697003 | |
| Excessive salivation | off-label use | 53827007 | |
| Rhinitis | off-label use | 70076002 | DOID:4483 |
| Seasonal allergic rhinitis | off-label use | 367498001 | |
| Brain damage | contraindication | 2470005 | |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Alcoholism | contraindication | 7200002 | |
| Hyperammonemia | contraindication | 9360008 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Disorder of autonomic nervous system | contraindication | 15241006 | |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Ventricular tachycardia | contraindication | 25569003 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hypovolemic shock | contraindication | 39419009 | |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Hyperactive behavior | contraindication | 44548000 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Acidosis | contraindication | 51387008 | |
| Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Peptic reflux disease | contraindication | 57643001 | |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Poisoning by phenobarbital | contraindication | 64921004 | |
| Arterial thrombosis | contraindication | 65198009 | |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Magnetic resonance imaging | contraindication | 113091000 | |
| Hypoalbuminemia | contraindication | 119247004 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Partial atrioventricular block | contraindication | 195039008 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Myocardial dysfunction | contraindication | 233928007 | |
| Arterial aneurysm | contraindication | 233981004 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Dyspnea | contraindication | 267036007 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Drowsy | contraindication | 271782001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
| Hypoxia | contraindication | 389086002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Porphyria | contraindication | 418470004 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.24 | acidic |
| pKa2 | 7.95 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9 | WOMBAT-PK | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.86 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 9.40 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 9.37 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.75 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Kd | 8.52 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 9.28 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Kd | 9.19 | CHEMBL | |||||
| Muscarinic receptor M1 | GPCR | Ki | 9.39 | CHEMBL | |||||
| Muscarinic acetylcholine receptor DM1 | GPCR | Ki | 9.15 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 10.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018401 | VUID |
| N0000146728 | NUI |
| D00138 | KEGG_DRUG |
| 6533-68-2 | SECONDARY_CAS_RN |
| 4018399 | VANDF |
| 4018401 | VANDF |
| 4018412 | VANDF |
| C0036442 | UMLSCUI |
| CHEBI:16794 | CHEBI |
| CHEMBL1187846 | ChEMBL_ID |
| CHEMBL569713 | ChEMBL_ID |
| DB00747 | DRUGBANK_ID |
| CHEMBL2251240 | ChEMBL_ID |
| CHEMBL1256744 | ChEMBL_ID |
| D012601 | MESH_DESCRIPTOR_UI |
| 3000322 | PUBCHEM_CID |
| 330 | IUPHAR_LIGAND_ID |
| 55-16-3 | SECONDARY_CAS_RN |
| DL48G20X8X | UNII |
| 9601 | RXNORM |
| 1472 | MMSL |
| 5444 | MMSL |
| 5445 | MMSL |
| 72365 | MMSL |
| d00986 | MMSL |
| 001719 | NDDF |
| 003458 | NDDF |
| 387409009 | SNOMEDCT_US |
| 387477005 | SNOMEDCT_US |
| 72870001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Transderm Scop | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0067-4346 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | NDA | 29 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6470 | PATCH | 1 mg | TRANSDERMAL | ANDA | 30 sections |
| Belladonna Alkaloids with Phenobartbital | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0440-7183 | TABLET | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
| scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2258 | SYSTEM | 1 mg | TRANSDERMAL | ANDA | 27 sections |
| Transderm Scop | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-553 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | NDA | 29 sections |
| Transderm Scop | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-553 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | NDA | 29 sections |
| Transderm Scop | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-553 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | NDA | 29 sections |
| Phenohytro | HUMAN PRESCRIPTION DRUG LABEL | 4 | 17856-0123 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Phenohytro | HUMAN PRESCRIPTION DRUG LABEL | 4 | 17856-0125 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Phenohytro | HUMAN PRESCRIPTION DRUG LABEL | 4 | 17856-0125 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| PHENOBARBITAL WITH BELLADONNA ALKALOIDS | HUMAN PRESCRIPTION DRUG LABEL | 4 | 17856-0162 | ELIXIR | 0.01 mg | ORAL | unapproved drug other | 16 sections |
| Donnatal | HUMAN PRESCRIPTION DRUG LABEL | 4 | 17856-0423 | ELIXIR | 0.01 mg | ORAL | unapproved drug other | 12 sections |
| RE-PB HYOS ELIXIR | HUMAN PRESCRIPTION DRUG LABEL | 4 | 21695-594 | ELIXIR | 0.01 mg | ORAL | Unapproved drug other | 11 sections |
| Belladonna Alkaloids with Phenobartbital | HUMAN PRESCRIPTION DRUG LABEL | 4 | 21695-890 | TABLET | 0.01 mg | ORAL | Unapproved drug other | 15 sections |
| QUADRAPAX | HUMAN PRESCRIPTION DRUG LABEL | 4 | 21695-970 | ELIXIR | 0.01 mg | ORAL | Unapproved drug other | 13 sections |
| Donnatal | HUMAN PRESCRIPTION DRUG LABEL | 4 | 42254-268 | TABLET | 0.01 mg | ORAL | Unapproved drug other | 15 sections |
| PHENOBARBITAL WITH BELLADONNA ALKALOIDS | HUMAN PRESCRIPTION DRUG LABEL | 4 | 42291-205 | ELIXIR | 0.01 mg | ORAL | unapproved drug other | 17 sections |
| Donnatal | HUMAN PRESCRIPTION DRUG LABEL | 4 | 42291-245 | TABLET | 0.01 mg | ORAL | unapproved drug other | 22 sections |
| Scopolamine Trandermal System | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-580 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine Trandermal System | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-580 | PATCH, EXTENDED RELEASE | 1 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5349 | PATCH | 1 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5349 | PATCH | 1 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-505 | PATCH, EXTENDED RELEASE | 1.50 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-505 | PATCH, EXTENDED RELEASE | 1.50 mg | TRANSDERMAL | ANDA | 30 sections |
| Scopolamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-505 | PATCH, EXTENDED RELEASE | 1.50 mg | TRANSDERMAL | ANDA | 30 sections |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | Human Prescription Drug Label | 4 | 50742-665 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | Human Prescription Drug Label | 4 | 50742-665 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | Human Prescription Drug Label | 4 | 50742-666 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | Human Prescription Drug Label | 4 | 50742-666 | ELIXIR | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide | Human Prescription Drug Label | 4 | 50742-667 | TABLET | 0.01 mg | ORAL | UNAPPROVED DRUG OTHER | 20 sections |